This question resolves positively if GiveWell gives a grant or publishes a recommendation that grants be given to fund Sayana® Press on or before December 31, 2026. Or if an organisations supplying Sayana® press is designated a "Top Charity" or a recipient of "All Funds" before the deadline. This resolves according to a statement from GiveWell or a credible news organisation.
It resolves "No" otherwise.
The most likely resolution mechanism is that GiveWell writes "yes" in the column "Have we recommended one or more grants to support this program?" in the “Sayana® Press” row of the GiveWell program reviews spreadsheet (https://docs.google.com/spreadsheets/d/1TG7WRU85p1SEjir-5qvIEg4kVG9a4Lnzdgwcub8aKSs/edit#gid=0) or a spreadsheet that supersedes it.
-- Note --
Can you find issues with this question. I will reward good comments with Mana.
-- Background --
GiveWell has recommended grants to over 10 charities over the years. They are currently investigating 12 charity areas with other areas of research in the pipeline including Sayana® Press.
The following sections are quoted from GiveWell’s explanation of the topic:
“Worldwide in 2015, 12 per cent of married or in-union women are estimated to have had an unmet need for family planning; that is, they wanted to stop or delay childbearing but were not using any method of contraception. The level was much higher, 22 per cent, in the least developed countries. Many of the latter countries are in sub-Saharan Africa, which is also the region where unmet need was highest (24 per cent)...
Sayana® Press is a three-month, progestin-only, all-in-one injectable contraceptive that combines the drug and needle in the Uniject™ injection system. Sayana Press is small, light, easy to use, and requires minimal training, making it especially suitable for community-based distribution—and for women to administer themselves through self-injection…
Sayana Press delivers the drug depot medroxyprogesterone acetate (DMPA, also known under the brand name Depo-Provera®) through subcutaneous (SC) injection via PATH's Uniject™ single-use prefilled syringes.8 The United Kingdom's National Institute for Health and Care Excellence (NICE) reviewed the available evidence and concluded that DMPA, administered through subcutaneous (SC) or intramuscular (IM) injection, is an effective contraceptive…
[However,] Sayana Press is associated with several side effects, including headaches, bleeding irregularities, weight gain, injection-site reactions, and loss of bone mineral density (BMD) (which may increase the risk of bone fractures)...
We are highly uncertain about the costs of charities' Sayana Press programs, how many recipients of Sayana Press through these programs would not have used modern contraception in absence of the programs, and philosophical judgments on the value of averting unintended pregnancies and providing contraception relative to the outcomes of our priority programs."
Related questions
I quite like the idea in a vacuum (assuming it is truly cost effective for the utils), but I do not think the optics of it are great. I feel there is (unfair) reputation risk to funding it.
I further think EA, post-FTX, is trying to be a bit more optics aware.
An RCT on injectables found that "Using an experiment in Zambia that varied whether women were given access to contraceptives alone or with their husbands, we find that women given access with their husbands were 19% less likely to seek family planning services, 25% less likely to use concealable contraception, and 27% more likely to give birth. However, women given access to contraception alone report a lower subjective well-being, suggesting a psychosocial cost of making contraceptives more concealable"
Estimated a 24% base rate among programs GiveWell listed in 2017 but had not given a grant too yet (https://www.givewell.org/research/intervention-reports/august-2017-version)